Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are leading causes of mortality worldwide. COPD and HF incidence and related mortality increase with age. These chronic diseases frequently coexist especially among elderly patients and share common pathophysiological mechanisms. Despite the well-recognized benefit of beta-blockers on cardiovascular mortality and morbidity, this class of dugs is often underused in elderly patients with concomitant HF and COPD. Evidences derived from trials and meta-analyses suggest that cardio-selective beta-blockers should not be avoided in patients with COPD, since the benefit of beta-blockers treatment seems to outweigh the possible side effects. In this review we will discuss common pathophysiological mechanisms involved in the development of COPD and HF and we will review the evidence derived from trials on beta-blocker use, safety and benefits among elderly patients.
|Number of pages||7|
|Journal||Giornale di Gerontologia|
|Publication status||Published - 2015|
ASJC Scopus subject areas
- Geriatrics and Gerontology